4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Enterprise Value of -$390.9 million for Q1 2026, down 21.61% year-over-year from -$498.6 million in Q1 2025, and up 2.92% quarter-over-quarter from -$402.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Enterprise Value for 8 consecutive years, with -$390.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 21.61% year-over-year to -$390.9 million; the TTM figure through Mar 2026 stood at -$390.9 million (down 21.61% YoY), while the FY2025 annual figure was -$402.7 million, up 5.23% from the prior year.
- Enterprise Value climbed to -$390.9 million in Q1 2026 per FDMT's latest filing, from -$402.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$200.5 million in Q1 2023 and bottomed at -$541.9 million in Q2 2024.
- Historically, Enterprise Value has averaged -$337.9 million across 5 years, with a median of -$310.3 million in 2023.
- Annual changes were most pronounced in 2024 — Enterprise Value tumbled 162.36% — and 2025, when it surged 45.89%.
- 4D Molecular Therapeutics' Enterprise Value stood at -$213.6 million in 2022, then plunged by 34.97% to -$288.2 million in 2023, then tumbled by 47.41% to -$424.9 million in 2024, then increased by 5.23% to -$402.7 million in 2025, then gained by 2.92% to -$390.9 million in 2026.
- Business Quant data shows FDMT's Enterprise Value at -$390.9 million in Q1 2026, -$402.7 million in Q4 2025, and -$305.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -361.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -361.33 Mn |
| Mar 31, 2026 | -390.89 Mn |
| Dec 31, 2025 | -402.66 Mn |
| Sep 30, 2025 | -305.06 Mn |
| Jun 30, 2025 | -293.23 Mn |
| Mar 31, 2025 | -321.44 Mn |
| Dec 31, 2024 | -424.88 Mn |
| Sep 30, 2024 | -501.89 Mn |
| Jun 30, 2024 | -541.95 Mn |
| Mar 31, 2024 | -525.91 Mn |
| Dec 31, 2023 | -288.23 Mn |
| Sep 30, 2023 | -319.66 Mn |
| Jun 30, 2023 | -310.34 Mn |
| Mar 31, 2023 | -200.45 Mn |
| Dec 31, 2022 | -213.55 Mn |
| Sep 30, 2022 | -227.72 Mn |
| Jun 30, 2022 | -241.09 Mn |
| Mar 31, 2022 | -236.15 Mn |
| Dec 31, 2021 | -247.78 Mn |
| Sep 30, 2021 | -161.68 Mn |